Therefore, it would be worthwhile to study whether the dose of peg-IFN α-2a could be lowered from 180 μg/week to 90 μg/week in combination with standard dose of ribavirin without compromising the efficacy of therapy in chronic hepatitis C patients. The gene discussed is IFNA1; the disease is chronic hepatitis C virus infection.